NURS 6521N Advanced Pharmacology Midterm Exam V2 - 100
Multiple Choice Questions with Explanations (Latest
Update) || Walden University - 200 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Advanced Pharmacology
Description This midterm exam covers advanced pharmacokinetics, pharmacodynamics, drug
interactions, adverse effects, and therapeutic management across major drug
classes including cardiovascular, endocrine, psychiatric, antimicrobial, and
oncology agents. Emphasis is on evidence-based prescribing, patient safety, and
clinical decision-making for nurse practitioners.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Analyze pharmacokinetic and pharmacodynamic principles to predict drug
behavior and optimize therapy.
2. Evaluate drug interactions and adverse effects to ensure safe prescribing across
diverse patient populations.
3. Apply clinical guidelines to select appropriate pharmacotherapy for complex
conditions.
Accreditation This exam aligns with AACN Essentials and NONPF competencies for advanced
practice nursing.
Page 1
,1. A patient with chronic kidney disease (eGFR 25 mL/min/1.73m²) requires
treatment for hypertension. Which of the following antihypertensive agents requires
the most significant dose adjustment in this patient and what is the primary reason?
A. Lisinopril, because it undergoes extensive hepatic metabolism and has active metabolites
that accumulate.
B. Atenolol, because it is primarily renally excreted unchanged and has a long half-life that
increases with declining renal function.
C. Amlodipine, because it is highly protein-bound and displaced by uremic toxins.
D. Hydrochlorothiazide, because it loses efficacy when eGFR falls below 30
mL/min/1.73m².
Answer: B. Atenolol, because it is primarily renally excreted unchanged and has a
long half-life that increases with declining renal function.
Atenolol is predominantly excreted unchanged by the kidneys; its half-life is
significantly prolonged in renal impairment, requiring dose reduction to avoid
bradycardia and hypotension. Lisinopril also requires dose adjustment (renally
eliminated), but among the options, atenolol has the most pronounced accumulation.
Amlodipine is hepatically metabolized with minimal renal excretion.
Hydrochlorothiazide becomes ineffective at low eGFR but does not accumulate.
2. A patient with type 2 diabetes and established atherosclerotic cardiovascular
disease (ASCVD) is being started on a GLP-1 receptor agonist. Which of the
following statements best describes the rationale for choosing this class over a DPP-4
inhibitor in this patient?
A. GLP-1 receptor agonists have a more favorable effect on weight loss and HbA1c
reduction compared to DPP-4 inhibitors.
B. DPP-4 inhibitors are contraindicated in patients with ASCVD due to increased risk of
major adverse cardiac events.
C. GLP-1 receptor agonists are preferred because they can be used in patients with severe
renal impairment without dose adjustment.
D. DPP-4 inhibitors increase the risk of pancreatitis, making them less safe in patients with
cardiovascular disease.
Answer: A. GLP-1 receptor agonists have a more favorable effect on weight loss
and HbA1c reduction compared to DPP-4 inhibitors.
In patients with ASCVD, GLP-1 receptor agonists (e.g., liraglutide, semaglutide) are
recommended due to proven cardiovascular benefit (reduction in MACE) and
additional benefits of weight loss and glycemic control. DPP-4 inhibitors are neutral for
cardiovascular outcomes but do not reduce MACE and have less effect on weight.
DPP-4 inhibitors are not contraindicated in ASCVD. GLP-1 RAs require dose
adjustment in renal impairment. Pancreatitis risk is similar between classes.
Page 2
,3. A patient on warfarin for atrial fibrillation is prescribed an antibiotic for a
urinary tract infection. Which of the following antibiotics is most likely to potentiate
the effect of warfarin through inhibition of vitamin K epoxide reductase complex
subunit 1 (VKORC1) and displacement from protein binding?
A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Nitrofurantoin
D. Amoxicillin
Answer: B. Trimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole (TMP-SMX) potentiates warfarin by inhibiting
VKORC1 (similar to warfarin's mechanism) and displacing warfarin from albumin,
leading to increased free warfarin and INR. Ciprofloxacin inhibits CYP1A2, which
metabolizes warfarin, but its effect is less pronounced. Nitrofurantoin and amoxicillin
have minimal interaction with warfarin.
4. A patient with major depressive disorder is started on a selective serotonin
reuptake inhibitor (SSRI). After 4 weeks, the patient reports no improvement.
Which of the following pharmacodynamic mechanisms best explains the typical
delay in therapeutic response to SSRIs?
A. SSRIs require time to reach steady-state plasma concentrations before serotonin reuptake
is inhibited.
B. The initial increase in synaptic serotonin activates somatodendritic 5-HT1A autoreceptors,
which reduces serotonin release until these receptors desensitize.
C. SSRIs have a slow dissociation rate from the serotonin transporter, requiring weeks to
achieve full occupancy.
D. The therapeutic effect depends on downstream changes in gene expression that take
weeks to occur.
Answer: B. The initial increase in synaptic serotonin activates somatodendritic
5-HT1A autoreceptors, which reduces serotonin release until these receptors
desensitize.
The delay in SSRI response is primarily due to activation of 5-HT1A autoreceptors on
raphe neurons, which initially decrease serotonin release. After chronic administration,
these autoreceptors desensitize, allowing full serotonergic transmission. Steady-state is
achieved within days, not weeks. Occupancy is near-maximal early. Gene expression
changes occur but are downstream of receptor desensitization.
Page 3
, 5. A patient with severe, refractory hypertension is started on a combination of
hydralazine and isosorbide dinitrate. Which of the following best describes the
rationale for this combination in the context of heart failure with reduced ejection
fraction (HFrEF)?
A. Both agents are direct vasodilators that reduce preload and afterload, but hydralazine also
increases heart rate, which is counteracted by isosorbide dinitrate.
B. Hydralazine is an arterial vasodilator and isosorbide dinitrate is a venodilator, providing
balanced hemodynamic effects that improve cardiac output.
C. The combination is specifically recommended for African American patients with HFrEF
due to genetic polymorphisms in nitric oxide production.
D. Isosorbide dinitrate is added to prevent hydralazine-induced lupus erythematosus by
reducing oxidative stress.
Answer: B. Hydralazine is an arterial vasodilator and isosorbide dinitrate is a
venodilator, providing balanced hemodynamic effects that improve cardiac output.
Hydralazine dilates arterioles (reducing afterload) and isosorbide dinitrate dilates veins
(reducing preload), together improving cardiac output in HFrEF. While hydralazine
can cause reflex tachycardia, isosorbide dinitrate does not directly counteract heart
rate. The combination is indeed recommended for African Americans, but the primary
rationale is hemodynamic. Hydralazine-induced lupus is not prevented by isosorbide.
6. A patient with generalized anxiety disorder is prescribed buspirone. Which of the
following statements about buspirone's mechanism and clinical use is correct?
A. Buspirone is a full agonist at 5-HT1A receptors and produces immediate anxiolytic
effects similar to benzodiazepines.
B. Buspirone has high affinity for dopamine D2 receptors, contributing to its antipsychotic
properties.
C. Buspirone requires several weeks to achieve therapeutic effect and does not cause
physical dependence.
D. Buspirone is effective for acute anxiety episodes and can be used as needed (PRN).
Answer: C. Buspirone requires several weeks to achieve therapeutic effect and does
not cause physical dependence.
Buspirone is a partial agonist at 5-HT1A receptors, with a delayed onset of 2-4 weeks,
and lacks abuse potential or physical dependence. It is not effective for acute anxiety
and is not a full agonist. It has minimal D2 affinity and no antipsychotic effects.
Page 4
Multiple Choice Questions with Explanations (Latest
Update) || Walden University - 200 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Advanced Pharmacology
Description This midterm exam covers advanced pharmacokinetics, pharmacodynamics, drug
interactions, adverse effects, and therapeutic management across major drug
classes including cardiovascular, endocrine, psychiatric, antimicrobial, and
oncology agents. Emphasis is on evidence-based prescribing, patient safety, and
clinical decision-making for nurse practitioners.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Analyze pharmacokinetic and pharmacodynamic principles to predict drug
behavior and optimize therapy.
2. Evaluate drug interactions and adverse effects to ensure safe prescribing across
diverse patient populations.
3. Apply clinical guidelines to select appropriate pharmacotherapy for complex
conditions.
Accreditation This exam aligns with AACN Essentials and NONPF competencies for advanced
practice nursing.
Page 1
,1. A patient with chronic kidney disease (eGFR 25 mL/min/1.73m²) requires
treatment for hypertension. Which of the following antihypertensive agents requires
the most significant dose adjustment in this patient and what is the primary reason?
A. Lisinopril, because it undergoes extensive hepatic metabolism and has active metabolites
that accumulate.
B. Atenolol, because it is primarily renally excreted unchanged and has a long half-life that
increases with declining renal function.
C. Amlodipine, because it is highly protein-bound and displaced by uremic toxins.
D. Hydrochlorothiazide, because it loses efficacy when eGFR falls below 30
mL/min/1.73m².
Answer: B. Atenolol, because it is primarily renally excreted unchanged and has a
long half-life that increases with declining renal function.
Atenolol is predominantly excreted unchanged by the kidneys; its half-life is
significantly prolonged in renal impairment, requiring dose reduction to avoid
bradycardia and hypotension. Lisinopril also requires dose adjustment (renally
eliminated), but among the options, atenolol has the most pronounced accumulation.
Amlodipine is hepatically metabolized with minimal renal excretion.
Hydrochlorothiazide becomes ineffective at low eGFR but does not accumulate.
2. A patient with type 2 diabetes and established atherosclerotic cardiovascular
disease (ASCVD) is being started on a GLP-1 receptor agonist. Which of the
following statements best describes the rationale for choosing this class over a DPP-4
inhibitor in this patient?
A. GLP-1 receptor agonists have a more favorable effect on weight loss and HbA1c
reduction compared to DPP-4 inhibitors.
B. DPP-4 inhibitors are contraindicated in patients with ASCVD due to increased risk of
major adverse cardiac events.
C. GLP-1 receptor agonists are preferred because they can be used in patients with severe
renal impairment without dose adjustment.
D. DPP-4 inhibitors increase the risk of pancreatitis, making them less safe in patients with
cardiovascular disease.
Answer: A. GLP-1 receptor agonists have a more favorable effect on weight loss
and HbA1c reduction compared to DPP-4 inhibitors.
In patients with ASCVD, GLP-1 receptor agonists (e.g., liraglutide, semaglutide) are
recommended due to proven cardiovascular benefit (reduction in MACE) and
additional benefits of weight loss and glycemic control. DPP-4 inhibitors are neutral for
cardiovascular outcomes but do not reduce MACE and have less effect on weight.
DPP-4 inhibitors are not contraindicated in ASCVD. GLP-1 RAs require dose
adjustment in renal impairment. Pancreatitis risk is similar between classes.
Page 2
,3. A patient on warfarin for atrial fibrillation is prescribed an antibiotic for a
urinary tract infection. Which of the following antibiotics is most likely to potentiate
the effect of warfarin through inhibition of vitamin K epoxide reductase complex
subunit 1 (VKORC1) and displacement from protein binding?
A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Nitrofurantoin
D. Amoxicillin
Answer: B. Trimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole (TMP-SMX) potentiates warfarin by inhibiting
VKORC1 (similar to warfarin's mechanism) and displacing warfarin from albumin,
leading to increased free warfarin and INR. Ciprofloxacin inhibits CYP1A2, which
metabolizes warfarin, but its effect is less pronounced. Nitrofurantoin and amoxicillin
have minimal interaction with warfarin.
4. A patient with major depressive disorder is started on a selective serotonin
reuptake inhibitor (SSRI). After 4 weeks, the patient reports no improvement.
Which of the following pharmacodynamic mechanisms best explains the typical
delay in therapeutic response to SSRIs?
A. SSRIs require time to reach steady-state plasma concentrations before serotonin reuptake
is inhibited.
B. The initial increase in synaptic serotonin activates somatodendritic 5-HT1A autoreceptors,
which reduces serotonin release until these receptors desensitize.
C. SSRIs have a slow dissociation rate from the serotonin transporter, requiring weeks to
achieve full occupancy.
D. The therapeutic effect depends on downstream changes in gene expression that take
weeks to occur.
Answer: B. The initial increase in synaptic serotonin activates somatodendritic
5-HT1A autoreceptors, which reduces serotonin release until these receptors
desensitize.
The delay in SSRI response is primarily due to activation of 5-HT1A autoreceptors on
raphe neurons, which initially decrease serotonin release. After chronic administration,
these autoreceptors desensitize, allowing full serotonergic transmission. Steady-state is
achieved within days, not weeks. Occupancy is near-maximal early. Gene expression
changes occur but are downstream of receptor desensitization.
Page 3
, 5. A patient with severe, refractory hypertension is started on a combination of
hydralazine and isosorbide dinitrate. Which of the following best describes the
rationale for this combination in the context of heart failure with reduced ejection
fraction (HFrEF)?
A. Both agents are direct vasodilators that reduce preload and afterload, but hydralazine also
increases heart rate, which is counteracted by isosorbide dinitrate.
B. Hydralazine is an arterial vasodilator and isosorbide dinitrate is a venodilator, providing
balanced hemodynamic effects that improve cardiac output.
C. The combination is specifically recommended for African American patients with HFrEF
due to genetic polymorphisms in nitric oxide production.
D. Isosorbide dinitrate is added to prevent hydralazine-induced lupus erythematosus by
reducing oxidative stress.
Answer: B. Hydralazine is an arterial vasodilator and isosorbide dinitrate is a
venodilator, providing balanced hemodynamic effects that improve cardiac output.
Hydralazine dilates arterioles (reducing afterload) and isosorbide dinitrate dilates veins
(reducing preload), together improving cardiac output in HFrEF. While hydralazine
can cause reflex tachycardia, isosorbide dinitrate does not directly counteract heart
rate. The combination is indeed recommended for African Americans, but the primary
rationale is hemodynamic. Hydralazine-induced lupus is not prevented by isosorbide.
6. A patient with generalized anxiety disorder is prescribed buspirone. Which of the
following statements about buspirone's mechanism and clinical use is correct?
A. Buspirone is a full agonist at 5-HT1A receptors and produces immediate anxiolytic
effects similar to benzodiazepines.
B. Buspirone has high affinity for dopamine D2 receptors, contributing to its antipsychotic
properties.
C. Buspirone requires several weeks to achieve therapeutic effect and does not cause
physical dependence.
D. Buspirone is effective for acute anxiety episodes and can be used as needed (PRN).
Answer: C. Buspirone requires several weeks to achieve therapeutic effect and does
not cause physical dependence.
Buspirone is a partial agonist at 5-HT1A receptors, with a delayed onset of 2-4 weeks,
and lacks abuse potential or physical dependence. It is not effective for acute anxiety
and is not a full agonist. It has minimal D2 affinity and no antipsychotic effects.
Page 4
